Cargando…

The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management

Detalles Bibliográficos
Autores principales:	Denault, Marie-Helene, Ho, Cheryl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080321/ https://www.ncbi.nlm.nih.gov/pubmed/37033344 http://dx.doi.org/10.21037/tcr-22-2843

Ejemplares similares

Foreword to ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
por: Paz-Ares, Luis
Publicado: (2020)

Summary of ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
por: Paz-Ares, Luis
Publicado: (2020)

PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
por: Käsmann, Lukas, et al.
Publicado: (2023)

Will Guiteau Receive the Benefit of a Doubt?
Publicado: (1881)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment
por: Agbarya, Abed, et al.
Publicado: (2022)

Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
por: Lau, Sally C.M., et al.
Publicado: (2021)

IDO1 Activity Predicts Lung Toxicity in Patients with Unresectable Stage III NSCLC and Chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2023)

Immunotherapy in the First-Line Setting in Wild-Type NSCLC
por: Denault, Marie-Hélène, et al.
Publicado: (2021)

Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2022)

Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?
por: Remon, Jordi, et al.
Publicado: (2022)

Follow-Up Imaging Guidelines for Patients with Stage III Unresectable NSCLC: Recommendations Based on the PACIFIC Trial
por: Ko, Jenny J., et al.
Publicado: (2023)

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
por: Alessi, Joao V., et al.
Publicado: (2023)

Drug trials in children: Doubts and dilemmas
por: Dalvi, Bharat
Publicado: (2008)

Atherosclerosis as an inflammatory disease: Doubts? No more
por: Vaccarezza, Mauro, et al.
Publicado: (2018)

A specialty forged on its doubts
Publicado: (2015)

Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC
por: Zhao, Qianqian, et al.
Publicado: (2019)

Treatment Patterns for Patients With Unresected Stage III NSCLC: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database
por: Shang, Shijie, et al.
Publicado: (2022)

Hypovitaminosis D and morbidity in critical illness: is there proof beyond reasonable doubt?
por: Venkatesh, Bala, et al.
Publicado: (2014)

Practical challenges in patients with stage III NSCLC receiving checkpoint inhibitors after chemoradiation
por: Shukla, Nikhil A, et al.
Publicado: (2020)

Cherish Your Exceptions, But Also Your Doubts
por: de Grey, Aubrey D.N.J.
Publicado: (2019)

The vital need for Allergy Training: removing the doubts
por: Papadopoulos, Nikolaos G, et al.
Publicado: (2013)

Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage Ⅲ nsclc in china
por: Jiang, Xiaotong, et al.
Publicado: (2022)

Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC
por: Malet, Julie, et al.
Publicado: (2023)

Quantitative spatial profiling of PD-1/PD-L1 interaction in patients with cancer
por: Hakozaki, Taiki
Publicado: (2023)

Commentary: Using central mechanical support devices: When in doubt, remember central cannulation
por: Schutz, Alexander, et al.
Publicado: (2020)

Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy
por: Vrankar, Martina, et al.
Publicado: (2020)

A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China
por: Li, Wei, et al.
Publicado: (2023)

Is it Possible to Predict Benefit from 5FU Adjuvant Therapy in Stage III Colon Cancer Patients?
por: Bonin, Serena
Publicado: (2015)

In silico trials of combination immuno-radiation for unresectable hepatocellular carcinoma
por: Mendiratta-Lala, Mishal, et al.
Publicado: (2023)

The cost of unresectable stage III or stage IV melanoma in Italy
por: Maio, Michele, et al.
Publicado: (2012)

Selected Patients with Unresectable Perihilar Cholangiocarcinoma (pCCA) Derive Long-Term Benefit from Liver Transplantation
por: Azad, Adiba I., et al.
Publicado: (2020)

Electro-convulsive Therapy: A Few Lingering Thoughts/Doubts!
por: Reddy, M. S.
Publicado: (2011)

The Utility of Anti-Covid-19 Desks in Italy, Doubts and Criticism
por: Bergamin, Marco, et al.
Publicado: (2020)

Elevated neutrophil‐to‐lymphocyte ratio (NLR) is associated with poorer progression‐free survival in unresectable stage III NSCLC treated with consolidation durvalumab
por: Nindra, Udit, et al.
Publicado: (2022)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

(18)F-FDG PET/CT to predict tumor PD-L1 expression and response to PD-(L)1 blockade in patients with non-small-cell lung cancer
por: Borm, Frank Johannes, et al.
Publicado: (2020)

Current status and future directions in unresectable stage III non-small cell lung cancer
por: Arellano, Esperanza Arriola, et al.
Publicado: (2020)

FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression
por: Abdayem, Pamela, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4tu7bpbf1pk5cf0k90jc8q56p2